Randomized trial to evaluate cardiometabolic and endothelial function in patients with plasma HIV-1 RNA suppression switching to darunavir/ritonavir with or without nucleoside analogues

HIV Clinical Trials

Volumn 14, Issue 4, 2013, Pages 140-148

  Guaraldi, G ^a   Zona, S ^a   Cossarizza, A ^a   Vernacotola, L ^b   Carli, F ^a   Lattanzi, A ^a   Beghetto, B ^a   Orlando, G ^a   De Biasi, S ^a   Termini, R ^b   Garau, M ^c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Medical Affairs Europe   (Italy)

^c SS Trinit Hospital   (Italy)

Author keywords

brachial artery reactivity; clinical trials; darunavir; nucleoside analogues; protease inhibitor monotherapy

Indexed keywords

DARUNAVIR PLUS RITONAVIR; INTEGRASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; BRACHIAL ARTERY; CARDIOMETABOLIC RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MALE; MONOTHERAPY; PARAMETERS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; BRACHIAL ARTERY; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; ENDOTHELIAL CELLS; FEMALE; HIV-1; HUMANS; MALE; MIDDLE AGED; NUCLEOSIDES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; VIRAL LOAD;

EID: 84881404726     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1404-140     Document Type: Article

References (25)

1. Hammer S, Eron J, Reiss P, et al. Antiretroviral treatment of adult HIV infection. 2008 recommendations of the International AIDS Society-USA Panel. JAMA. 2008; 300(5): 555-570
2. US Department for Health and Social Security. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, January 10, 2011. http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7. Accessed March 2011.
3. European AIDS Clinical Society (EACS). Guidelines for the clinical management of HIV infected adults in Europe. http://www. europeanaidsclinicalsociety.org/guidelinespdf/1-Treatment-of-HIV-Infected- Adults.pdf. Accessed September 2010.
4. Arribas J, Horban A, Gerstoft J, et al. The MONET trial: Darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010; 24(2):223-230.
5. Clumeck N, Rieger A, Banhegyi D, et al. 96 week results from the MONET trial: A randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA< 50 copies/mL at baseline [published online ahead of print June 2011]. J Antimicrob Chemother.
6. Katlama C, Valentin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: A randomized open-label non-inferiority trial, MONOI-ANRS 136. AIDS. 2010; 24(15):2365-2374.
7. Valentin M, Flandre P, Kolta S, et al. Fat tissue distribution changes in HIV-infected patients with viral suppression treated with darunavir-ritonavir monotherapy versus 2NRTIs + DRV/r in the MONOI-ANRS 136 randomised trial: Results at 48 weeks [abstract O-262]. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 2010; San Francisco, USA.
8. Randell P, Jackson A, Zhong L, Yale K, Moyle G. The impact of tenofovir on insulin sensitivity and lipids in healthy volunteers [abstract H-2307]. Presented at: 48th Annual ICAAC/IDSA Meeting; October 2008; Washington, DC, USA.
9. Grunfeld C, Kotler D, Arnett D, et al. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation. 2008; 118:1-9.
10. Guaraldi G, Stentarelli C, Zona S, et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis. 2010; 208:222-227.
11. Law M, Friis-Moller N, El-Sadr W, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: Comparison with observed events in the D:A:D study. HIV Med. 2006; 7:218-230.
12. Deanfield J, Halcox J, Rabelink T. Endothelial function and dysfunction: Testing and clinical relevance. Circulation. 2007; 115:1285-1295. (Pubitemid 46594773)
13. Yeboah J, Crouse J, Hsu F, Burke G, Herrington D. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: The Cardiovascular Health Study. Circulation. 2001; 104:257-262.
14. Boos C, Lip G, Blann A. Circulating endothelial cells in cardiovascular disease. J Am Coll Cardiol. 2006; 48: 1538-1547. (Pubitemid 44550075)
15. Solages A, Vita J, Thornton D, et al. Endothelial function in HIV-infected persons. Clin Infect Dis. 2006; 42:1325-1332.
16. Torriani F, Komarow L, Parker R, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral- naive subjects before and after starting potent antiretroviral therapy. The ACTG 5142s. J Am Coll Cardiol. 2008; 52:569-576.
17. Murphy R, Berzins B, Zala C, et al. Change to atazanavir/ ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS. 2010; 24:885-890.
18. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial dependent fl ow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39:257-265. (Pubitemid 34084631)
19. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. Nature Rev Cancer. 2006; 6:835-845. (Pubitemid 44629895)
20. Barbieri D, Abbracchio MP, Salvioli S, et al. Apoptosis by 2-chloro-2′ -deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. Neurochem Int. 1998; 32:493-504. (Pubitemid 28287203)
21. Nemes E, Lugli E, Bertoncelli L, et al. CD4+ T cell differentiation, Treg and gag-specific T lymphocytes are unaffected by CD4-guided treatment interruption and therapy resumption. AIDS. 2011; 25:1443-1453.
22. Flammer A, Vo N, Hermann F, et al. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: A randomized controlled trial. Heart. 2009; 95:385-390.
23. Hunt P, Sinclair E, Epling I, et al. Impaired endothelial function is associated with increased frequencies of CCR5+ and HIV-specific T cells during treated HIV infection [abstract 160]. Presented at: 18th Conference on Retroviruses and Opportunistic Infections (CROI); February 2011; Boston, MA, USA.
24. Bots M, Westerink J, Rabelink T, de Koning E. Assessment of fl ow-mediated vasodilation (FMD) of the brachial artery: Effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J. 2005; 26:363-368. (Pubitemid 40283095)
25. Hsue P, Hunt P, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS. 2009; 23(15):2021-2027.